67 related articles for article (PubMed ID: 38532893)
1. Transcriptome and metabolome sequencing identifies glutamate and LPAR1 as potential factors of anlotinib resistance in thyroid cancer.
Liu B; Peng Y; Su Y; Diao C; Qian J; Zhan X; Cheng R
Anticancer Drugs; 2024 Jun; ():. PubMed ID: 38820067
[TBL] [Abstract][Full Text] [Related]
2. Effective treatment of anlotinib in giant delayed pulmonary metastasis of osteosarcoma: a case report and literature review.
Long ZY; Lu Y; Li M; Chen G; Shi L; Xiao X; Bai Y; Zhang HM; Wang Z
Ann Palliat Med; 2021 Jun; 10(6):7073-7082. PubMed ID: 33548989
[TBL] [Abstract][Full Text] [Related]
3. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development.
Shen G; Zheng F; Ren D; Du F; Dong Q; Wang Z; Zhao F; Ahmad R; Zhao J
J Hematol Oncol; 2018 Sep; 11(1):120. PubMed ID: 30231931
[TBL] [Abstract][Full Text] [Related]
4. BMS-794833 reduces anlotinib resistance in osteosarcoma by targeting the VEGFR/Ras/CDK2 pathway.
Meng Q; Han J; Wang P; Jia C; Guan M; Zhang B; Zhao W
J Bone Oncol; 2024 Apr; 45():100594. PubMed ID: 38532893
[TBL] [Abstract][Full Text] [Related]
5. Tocilizumab (monoclonal anti-IL-6R antibody) reverses anlotinib resistance in osteosarcoma.
Xu J; Chen C; Sun K; Shi Q; Wang B; Huang Y; Ren T; Tang X
Front Oncol; 2023; 13():1192472. PubMed ID: 37404767
[TBL] [Abstract][Full Text] [Related]
6. Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma.
Wang G; Sun M; Jiang Y; Zhang T; Sun W; Wang H; Yin F; Wang Z; Sang W; Xu J; Mao M; Zuo D; Zhou Z; Wang C; Fu Z; Wang Z; Duan Z; Hua Y; Cai Z
Int J Cancer; 2019 Aug; 145(4):979-993. PubMed ID: 30719715
[TBL] [Abstract][Full Text] [Related]
7. PI3K inhibitor impairs tumor progression and enhances sensitivity to anlotinib in anlotinib-resistant osteosarcoma.
Chen C; Guo Y; Huang Q; Wang B; Wang W; Niu J; Lou J; Xu J; Ren T; Huang Y; Guo W
Cancer Lett; 2022 Jun; 536():215660. PubMed ID: 35318116
[TBL] [Abstract][Full Text] [Related]
8. The Effect of Anlotinib Combined with anti-PD-1 in the Treatment of Gastric Cancer.
Zheng W; Sun G; Li Z; Wu F; Sun G; Cao H; Zhou J; Ma Y
Front Surg; 2022; 9():895982. PubMed ID: 35495754
[TBL] [Abstract][Full Text] [Related]
9. The function and mechanism of PSMD14 in promoting progression and resistance to anlotinib in osteosarcoma.
Liu Z; Wang X; Li C; Zhao R
Cancer Cell Int; 2023 Dec; 23(1):309. PubMed ID: 38053170
[TBL] [Abstract][Full Text] [Related]
10. Tyrosine kinase inhibitors in osteosarcoma: Adapting treatment strategiesa.
Assi A; Farhat M; Hachem MCR; Zalaquett Z; Aoun M; Daher M; Sebaaly A; Kourie HR
J Bone Oncol; 2023 Dec; 43():100511. PubMed ID: 38058514
[TBL] [Abstract][Full Text] [Related]
11. Exploring the crosstalk between endothelial cells, immune cells, and immune checkpoints in the tumor microenvironment: new insights and therapeutic implications.
Fang J; Lu Y; Zheng J; Jiang X; Shen H; Shang X; Lu Y; Fu P
Cell Death Dis; 2023 Sep; 14(9):586. PubMed ID: 37666809
[TBL] [Abstract][Full Text] [Related]
12. Vascular Growth in Lymphomas: Angiogenesis and Alternative Ways.
Ribatti D; Tamma R; Annese T; d'Amati A; Ingravallo G; Specchia G
Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370872
[TBL] [Abstract][Full Text] [Related]
13. Raltitrexed enhanced antitumor effect of anlotinib in human esophageal squamous carcinoma cells on proliferation, invasiveness, and apoptosis.
Zhen H; Tian J; Li G; Zhao P; Zhang Y; Che J; Cao B
BMC Cancer; 2023 Mar; 23(1):207. PubMed ID: 36870981
[TBL] [Abstract][Full Text] [Related]
14. Managing the immune microenvironment of osteosarcoma: the outlook for osteosarcoma treatment.
Tian H; Cao J; Li B; Nice EC; Mao H; Zhang Y; Huang C
Bone Res; 2023 Feb; 11(1):11. PubMed ID: 36849442
[TBL] [Abstract][Full Text] [Related]
15. Current progress and open challenges for applying tyrosine kinase inhibitors in osteosarcoma.
Chen C; Shi Q; Xu J; Ren T; Huang Y; Guo W
Cell Death Discov; 2022 Dec; 8(1):488. PubMed ID: 36509754
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
